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Abstract
Background: The b2-adrenergic receptor (b2AR) is expressed on numerous cell-types including airway smooth muscle cells
and cardiomyocytes. Drugs (agonists or antagonists) acting at these receptors for treatment of asthma, chronic obstructive
pulmonary disease, and heart failure show substantial interindividual variability in response. The ADRB2 gene is polymorphic
in noncoding and coding regions, but virtually all ADRB2 association studies have utilized the two common nonsynonymous
coding SNPs, often reaching discrepant conclusions.
Methodology/Principal Findings: We constructed the 8 common ADRB2 haplotypes derived from 26 polymorphisms in the
promoter, 59UTR, coding, and 39UTR of the intronless ADRB2 gene. These were cloned into an expression construct lacking a
vector-based promoter, so that b2AR expression was driven by its promoter, and steady state expression could be modified
by polymorphisms throughout ADRB2 within a haplotype. ‘‘Whole-gene’’ transfections were performed with COS-7 cells and
revealed 4 haplotypes with increased cell surface b2AR protein expression compared to the others. Agonist-promoted
downregulation of b2AR protein expression was also haplotype-dependent, and was found to be increased for 2 haplotypes.
A phylogenetic tree of the haplotypes was derived and annotated by cellular phenotypes, revealing a pattern potentially
driven by expression.
Conclusions/Significance: Thus for obstructive lung disease, the initial bronchodilator response from intermittent
administration of b-agonist may be influenced by certain b2AR haplotypes (expression phenotypes), while other haplotypes
may influence tachyphylaxis during the response to chronic therapy (downregulation phenotypes). An ideal clinical
outcome of high expression and less downregulation was found for two haplotypes. Haplotypes may also affect heart
failure antagonist therapy, where b2AR increase inotropy and are anti-apoptotic. The haplotype-specific expression and
regulation phenotypes found in this transfection-based system suggest that the density of genetic information in the form
of these haplotypes, or haplotype-clusters with similar phenotypes can potentially provide greater discrimination of
phenotype in human disease and pharmacogenomic association studies.
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Introduction
The b2-adrenergic receptor (b2AR) is a member of the G-protein
coupled receptor superfamily (GPCR), and is expressed on virtually all
cell-types [1]. The catecholamines epinephrine and to a lesser extent
norepinephrine are the endogenous agonists which activate these
r e c e p t o r sa sp a r to ft h es y m p a t h e t i c nervous system. Of particular
interest for therapeutic purposes have been b2AR expressed on smooth
muscle cells of the airway which promote bronchodilatation and those
expressed on cardiomyocytes which promote cardiac contractility. b-
agonists acting on airway smooth muscle b2AR, and non-selective b-
blockers acting on b2-a n db1AR on cardiomyocytes, are standard
treatments of obstructive lung disease and heart failure, respectively.
The b2AR gene (ADRB2), which is localized to 5q31-32, is
intronless and encodes a protein of 413 amino acids that has a
seven transmembrane topology typical of the superfamily. The
amino-terminus is extracellular while the carboxy-terminus is
intracellular. Ligand binding occurs in a ‘‘pocket’’ formed by
residues of the transmembrane domains. The substantial interin-
dividual variability in the responses to b-agonists [2] and
antagonists [3] has prompted examination of the gene for common
polymorphisms. Our identification [4] of coding polymorphisms of
the b2AR in 1993 represented the first report of discreet
nonsynonymous polymorphisms of any GPCR and prompted a
host of subsequent clinical association studies [5,6]. The two
common non-synonymous single nucleotide polymorphisms
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11819(SNPs, Table 1) are at nucleic acid 46 resulting in amino acid
position 16 being either Arg or Gly, and at nucleic acid 79
resulting in amino acid position 27 being Glu or Gln [4]. These
polymorphisms are localized to the extracellular amino-terminus,
and have a subtle effect on agonist-promoted downregulation of
receptor expression when studied in a cell-based system where
transfections of vectors containing only the open reading frames
were carried out [7]. Virtually all association studies for
pharmacogenomic effects have utilized these coding polymor-
phisms with variable or inconsistent results (reviewed in [5,8]).
These inconsistent associations have prompted examination of the
promoter, 59UTR, and 39UTR of ADRB2 for additional
polymorphisms. Initial studies by our group indicated multiple
polymorphisms in these other regions, many of which were not in
significant linkage disequilibrium with the coding polymorphisms
[9–11]. Thus there is the potential for a more precise ADRB2
genetic signature for association studies, which may be particularly
important if these other polymorphisms affect receptor expression
or agonist mediated regulation of the receptor. Of interest is the
potential for interaction between polymorphisms, such as
promoter polymorphisms that alter transcription and coding
polymorphisms that alter protein stability, so that the net effect
could be a composite of multiple variants on the phenotype. Based
on our previous studies of this intronless gene, there appear to be
17 common SNPs in the 59 upstream region (3500 bases 59 of the
initiator ATG), 7 coding SNPs (3 nonsynonymous), and one SNP
and a variable poly-C tract in the 39UTR (Table 1). In subjects of
European or African ancestry, these are found to be arranged into
eight haplotypes with frequencies of .0.05 in at least one racial
group [11]. These common haplotypes have been named based on
our initial haplotypes that only considered the 59-flanking and
coding regions [9], and are denoted I-1, II-1, IV-1, IV-2, IV-3, IV-
4, VI-1 and VI-2 (Table 1). The cellular phenotypes of these
combinations of SNPs, based on the common haplotypes, have not
been determined. Because of the intronless nature of ADRB2,
‘‘whole-gene’’ transfections are possible and provide an opportu-
nity to ascertain the effects of the combination of SNPs, as they
appear in nature, on cellular phenotypes. The current work utilizes
this approach, where we identify phenotypes which have not been
previously appreciated by studying individual SNPs or limited
groups of SNPs.
Results and Discussion
The constructs utilized for transfection consisted of 5,580 bp of
ADRB2 (23685 to +1895) which represents contiguous promoter,
59UTR, coding and 39UTR sequence up to the poly-A
termination site. Site-directed mutagenesis and digestion-ligation
reactions were utilized to construct the eight haplotypes, which
were verified by sequencing (Table 1). The final constructs
were cloned into a modification of the pcDNA3.1(+) expression
vector in which the CMV promoter was removed (denoted
pcDNA3.1(+)/DCMV, see Methods). Thus expression of the
b2AR was driven by its own promoter, and influences of promoter,
59UTR, coding and 39UTR polymorphisms, in their appropriate
context (i.e., the eight haplotypes) could be ascertained. Studies
were performed in transfected COS-7 cells. Two major pheno-
types were considered: baseline b2AR protein expression, and,
agonist-promoted downregulation of receptor protein expression.
b2AR expression was ascertained using a highly quantitative
125
I-cyanopindolol (
125I-CYP) radioligand binding assay. In the
absence of transfection, such binding revealed ,10 fmol/mg
expression in COS-7 cells, while transfection with the whole-gene
vectors provided for ,1,000 fmol/mg human b2AR expression.
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Phenotypes of ADRB2 Haplotypes
PLoS ONE | www.plosone.org 2 July 2010 | Volume 5 | Issue 7 | e11819The results from these transfection studies are shown in Figure 1.
Haplotypes I-1, II-1, IV-1 and IV-3 had higher expression levels
than the other four haplotypes. To verify the radioligand binding
method for ranking expression by haplotypes, Western blots were
performed as shown in Figure 2 using a monoclonal antibody
directed to a non-polymorphic region of the receptor protein. As
indicated, haplotypes IV-1 and IV-3 had greater immunoreactivity
at the expected molecular weight compared to haplotypes IV-4
and VI-2, consistent with the results from radioligand binding.
The ADRB2 mRNA expression, ascertained by quantitative
RT-PCR [12], did not necessarily mirror b2AR protein expression
for each haplotype (Figure 3A). The relationship between protein
expression and mRNA (essentially showing the ratio for each
haplotype) is shown in Figure 3B. As shown, there is a trend
towards a statistically significant overall correlation between
ADRB2 mRNA and b2AR protein (r
2=0.47, p=0.06). However,
when formally tested two haplotypes (I-1 and VI-1) had b2AR/
ADRB2 ratios that differed by 1 standard deviation from the mean
ratio. Indeed, removal of either of these outliers increases the r
2
value to ,0.60 with significance at p=0.03. The basis for this
difference in relative levels of mRNA vs. protein expression is not
readily apparent by inspection of haplotype sequence. Haplotype
VI-1 differs from its closest haplotype (VI-2, a haplotype that is
consistent with the regression line) by a single nucleotide within the
59-flanking region at position 23159 (C or T). On the other hand,
VI-1 differs from the regression-conforming haplotype II-1 by 25
SNPs. A similar analysis with I-1 reveals multiple differences in
sequence between it and all other seven haplotypes. Taken
together, these results further support the notion that, for most
haplotypes, multiple SNPs are likely interacting to ultimately
establish phenotype.
We next assessed the agonist-promoted downregulation pheno-
type, which may be relevant to tachyphylaxis during prolonged
exogenous or endogenous agonist exposure [13]. Eighteen hours
after transfection, cells were exposed to vehicle (0.1 mM ascorbic
acid) or the agonist isoproterenol (10 mM) for 48 hours, washed,
and cell membranes prepared.
125I-CYP radioligand binding was
performed, and the results are shown in Figure 4 compared to
untreated cells. Two haplotypes (I-1 and IV-3) showed greater
extents of agonist-promoted downregulation compared to the
other five. One potential concern regarding defining the
downregulation phenotype based on a percentage of the untreated
(baseline) expression is a confoundment from differences in
baseline expression. However, we found no evidence for any
relationship between baseline levels of expression and the %
downregulation (Figure 5).
In terms of haplotypes predicting clinical responsiveness to b-
agonists in asthma, our results suggest that these phenotypes are
complex and can segregate as shown in Figure 6. For purposes of
this grouping, expression is defined as ‘‘reference’’ or ‘‘increased,’’
and agonist-promoted downregulation as ‘‘reference’’ or ‘‘in-
creased.’’ As shown, then, the haplotypes segregate into three
groups: reference expression and downregulation, increased
expression with reference downregulation, and increased expres-
sion with increased downregulation. These are designated as
groups A (haplotypes IV-2, IV-4, VI-1 and VI-2), B (haplotypes II-
1 and IV-1) and C (haplotypes I-1 and IV-3). Using group A as the
reference, patients in group C would be predicted to have a high
initial bronchodilating response to b-agonist, but would experience
the greatest tachyphylaxis to chronic administration. On the other
hand, patients in group B would also have a high initial response,
but would experience less tachyphylaxis, so the overall best clinical
response would be with these patients, which have haplotypes II-1
and IV-1. Although no studies have utilized these full haplotypes,
there are some that have assessed potential associations between
limited haplotypes, genotype combinations, or individual SNPs
and b-agonist phenotypes in asthma [5], which can be interpreted
to conform to the dual phenotypic groups of Figure 6. However,
each study showed variability within the limited genetically-
defined groups, consistent with additional genetic variations
potentially represented by the extended haplotypes, contributing
to phenotypic noise.
A phylogenetic analysis of the b2AR haplotypes was undertaken
with an overlay of the expression phenotypes, and the dual
phenotypes (Figure 7). Two ancestral lineages are noted (L1, L2).
L1 subsequently evolved to the two indicated haplotypes, both of
which have the increased expression phenotype. L2 underwent a
more complex evolution resulting in two major lineages, L2(1) and
L2(2). The former consists of two haplotypes both with the
reference expression phenotype. L2(2) segregates into a single,
distinct, increased-expression haplotype, and a three-haplotype
clade consisting of two reference-expression haplotypes and one
increased-expression haplotype. This latter haplotype (IV-1) differs
from its nearest neighbor (IV-2) by one additional C in a poly-C
tract in the 39UTR. This may represent an ancestral replication
error along this repetitive sequence of up to 14 C’s. While there
appears to be some consistency with the tree and expression
phenotype, there was no readily discernible pattern with the dual
phenotypic groups A, B and C of Figure 6. And furthermore, the
increased agonist-promoted downregulation haplotypes I-1 and
Figure 1. b2AR protein expression phenotypes of the common
ADRB2 haplotypes. COS-7 cells were transfected with constructs
representing the b2AR haplotypes shown in Table 1. Receptor protein
expression was determined by quantitative radioligand binding. Results
are from 7 experiments. *, p,0.05 vs. the other haplotypes.
doi:10.1371/journal.pone.0011819.g001
Figure 2. Western blots confirm the radioligand binding
method for ranking expression. Monoclonal antibody to a non-
polymorphic region of the b2AR protein was utilized to confirm the
radioligand binding method for ranking expression phenotypes of the
b2AR haplotypes. Shown is a single experiment revealing higher
expression of haplotypes IV-1 and IV-3 compared to IV-4 and VI-2 b2AR
protein at the expected molecular weight (,79 kDa). These results are
consistent with those from radioligand binding of Figure 1. The control
antibody was to Na
+/K
+-ATPase, a cell membrane protein.
doi:10.1371/journal.pone.0011819.g002
Phenotypes of ADRB2 Haplotypes
PLoS ONE | www.plosone.org 3 July 2010 | Volume 5 | Issue 7 | e11819IV-3 are not in the same lineages (Figure 7) and differ by 12 SNPs
(Table 1). Taken together, this may imply that ADRB2 evolution
was driven by b2AR expression rather than downregulation or the
dual phenotype. This interpretation is consistent with most b2AR
in the body being activated by circulating epinephrine, which
shows variability in plasma concentration [14] but rarely reaches
the high concentrations necessary for downregulation. Neverthe-
less, the high concentrations of b-agonist achieved during
pharmacologic therapy do promote b2AR downregulation in lung
cells [15], so this component of the dual phenotype should be
considered in grouping haplotypes for potential clinical associa-
tions with therapeutic response.
In conclusion, we have utilized the most common ADRB2
haplotypes (allele frequency of 0.05 or greater) to ascertain
expression and agonist-promoted downregulation. The full
intronless gene was cloned into a promoterless expression vector,
so that phenotypes could be manifested by polymorphisms in the
promoter, 59UTR, coding, or 39UTR regions. The great majority
of association studies in asthma (and other diseases) which have
considered the ADRB2 as a candidate gene for risk, severity or
other clinical phenotype, or as a pharmacogenomic locus, have
utilized one or both of the nonsynonymous coding polymorphisms.
The results of these association studies range from highly
significant associations [16] to the lack of any association [17].
While the study designs are virtually always different, which could
explain these inconsistencies, we have been concerned that these
limited polymorphisms do not provide a sufficient density of
genetic information to discriminate phenotypes. Indeed, there are
Figure 4. Agonist-promoted downregulation phenotypes of
the common ADRB2 haplotypes. Transfected COS-7 cells were
exposed to media alone or media with 10 mM isoproterenol for
48 hours. b2AR protein expression was determined by quantitative
radioligand binding. The results are from 7 experiments. *, %
downregulation from the untreated state differs at p,0.05 vs. all other
haplotypes.
doi:10.1371/journal.pone.0011819.g004
Figure 5. Lack of a relationship between baseline b2AR
expression and the % downregulation. The agonist-promoted
downregulation, expressed as a percentage, was plotted against
baseline b2AR protein expression. There was no relationship
(r
2=0.001, p.0.9) between the initial expression of b2AR and the
extent of downregulation. Results are from the 7 experiments of
Figure 4.
doi:10.1371/journal.pone.0011819.g005
Figure 3. ADRB2 mRNA levels of the transfected b2AR haplo-
types. (A) mRNA levels for haplotypes IV-1 and IV-3 are higher, and I-1
lower, than levels of the other haplotypes. Results are from 6
experiments. *, p,0.05 vs. the other haplotypes. (B) relationship
between ADRB2 mRNA levels and b2AR protein expression. The r
2 for
this relationship was 0.47. Two haplotypes (VI-1 and I-1) are greater
than 1 standard deviation from the mean b2AR/ADRB2 ratio.
doi:10.1371/journal.pone.0011819.g003
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within ADRB2 [9]. To begin to coalesce the .26 polymorphisms
in ADRB2 with cellular phenotypes, in the specific combinations
that are observed in the population, we constructed the eight
common haplotypes. We note that there are little or no ‘‘spare
b2AR’’ in airway smooth muscle in relation to relaxation [1], so
the ,20–40% lower expression observed between some haplo-
types could be related to clinically significantly lower bronchodi-
latory responses to b-agonist. A similar close relationship between
receptor expression and function is present in cardiomyocytes
where the b2AR subtype increases inotropy and acts to inhibit
certain apoptosis events in progressive heart failure when
catecholamine levels are elevated [18]. Thus non-selective b-
blocker efficacy could be affected by b2AR haplotype. The other
phenotype examined, receptor downregulation, is also relevant to
therapeutic efficacy since this represents a major mechanism of
tachyphylaxis during chronic agonist exposure. Association studies
using full b2AR haplotypes with b-agonists in obstructive lung
disease, or b-blockers in heart failure, have not been carried out to
date. Given the phenotypes that we have defined, it would appear
appropriate to carry out such studies with the haplotypes, or
groups of haplotypes with similar cellular phenotypes. Such an
approach may improve the predictivenesss of ADRB2 variation
with relevant clinical phenotypes and resolve discrepancies
between studies.
Methods
Expression Vectors
The expression vector pcDNA 3.1(+) (Invitrogen, Carlsbad, CA,
USA) was mutated to remove the CMV promoter by sequential
digestion with MluI and NheI followed by blunt-end ligation. This
modified promoterless vector is denoted pcDNA 3.1(+)/DCMV
and the full ADRB2 haplotypes (with the ADRB2 promoter) were
inserted into the Hind III/Xba1 sites. To generate the eight
ADRB2 haplotypes, the bacterial artificial chromosome RP11-
44B19 was used as the template to amplify ADRB2 (the haplotype
IV-1 form). Several rounds of site-directed mutagenesis by
methods previously described [19] were utilized to generate
mutations at the 26 variable sites, so as to construct the eight
Figure 6. Stratification matrix. The phenotypes derived from the in
vitro cell-based studies are stratified in a 262 matrix according to
baseline b2AR expression and the extent of agonist-promoted
downregulation. Three bins were populated as shown and are denoted
A, B, C for clarity.
doi:10.1371/journal.pone.0011819.g006
Figure 7. Phylogenetic tree of b2AR haplotypes with phenotypic annotation. Shown is a phylogenetic tree constructed as indicated in
Methods with the 8 b2AR haplotype sequences. Shown are the expression phenotypes (I, increased; R, reference) and the dual phenotypes that
incorporate expression and downregulation (denoted A, B, C from Figure 6). L1 and L2 represent the two ancestral lineages, while L2(1) and L2(2) are
lineages from L2.
doi:10.1371/journal.pone.0011819.g007
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construct was performed to verify the nucleotide changes and the
integrity of the ADRB2.
Cell Culture and Transfections
COS-7 cells (obtained from American Type Culture Collection)
were grown in Dulbecco’s modified Eagle’s medium with 10% fetal
calf serum, 100 units/ml penicillin and 100 mg/ml streptomycin
and for all conditions were maintained at 37u in a 95% air 5% CO2
environment. Transfections were carried out using methods
previously described [20]. Briefly, 5.0 mg haplotype construct with
15 ml Lipofectamine 2000 (Invitrogen) were added to 10
7 cells and
incubated for 6 hours. Then, fresh media was added and the media
changed the next day. Eighteen hours after transfection the cells
were treated with vehicle (0.1 mM ascorbic acid, representing
baseline) or the b-agonist isoproterenol in the media for 48 hours,
with an exchange of media and fresh isoproterenol after 24 hours.
Radioligand Binding and Western Blots
Attached cells werewashed three times with PBS and then scraped
in 5 mM Tris (pH 7.40) 2 mM EDTA at 4u and then centrifuged at
33,0006g for 15 min. Membranes were resuspended in 75 mM Tris
(pH 7.40), 12 mM MgCl2, 2 mM EDTA and radioligand binding
with
125I-CYP carried out in triplicate as described [21]. Co-
incubations with propranolol (10 mM) were used to define non-
specific binding. Reactions were terminated by dilution in cold buffer
and bound radioligand separated from free radioligand by vacuum
filtration over glass fiber filters. The filters were counted in a gamma
counter, and specific binding calculated as total minus nonspecific
binding normalized to protein and expressed as fmol/mg. For
Western blots, 15 mg of protein was electrophoresed through 10%
SDS-polyacrylamide gels and transferred to nitrocellulose mem-
branes as described [19]. Membranes were incubated with antibodies
to b2AR (1:200 dilution, Santa Cruz) or Na
+/K
+-ATPase (1:200
dilution, Santa Cruz) for 1 hour and processed using enhanced
chemiluminescence (GE Healthcare).
Quantitative RT-PCR
RNA was prepared using TRIZOL (Invitrogen) as described
[22]. Reverse transcriptase reactions were carried out with
Moloney murine leukemia virus reverse transcriptase (MultiScribe,
Applied Biosystems, Foster City, CA, USA), 500 ng of extracted
RNA, and random hexamer primers. Real time PCR was carried
out with 2 ml of diluted reverse transcription reaction using
methods previously described [12]. The TaqMan probe and
primers sets were from Applied Biosystems for ADRB2
(Hs00240532_s1), which provided an amplicon of 66 bp repre-
senting nucleotides 500–565 of the coding region. For the control
gene, probe and primer sets for phosphoglycerate kinase 1 (PGK2)
were utilized (Applied Biosystems 4326318E) which provides for
an amplicon of 75 bp. Reactions were carried out in an Applied
Biosystems 7300 RT-PCR system. Threshold cycle (Ct) values
were obtained (,15 for ADRB2 and ,23 for PGK2) and relative
mRNA levels calculated using a 2
2DCt method [23].
Phylogenetic modeling
A phylogenetic tree was constructed using methods similar to
those that we have previously described [24,25]. The unweighted
pair group method with arithmetic mean was utilized with the
maximum likelihood model to estimate evolutionary distance;
1,000 bootstrap sampling was performed.
Statistical Analysis
Data are shown as mean 6 standard error. Statistical
comparisons were by ANOVA with post-hoc 2-way t-tests.
Significance was considered when p,0.05.
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